Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose

Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward SANTA MONICA, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”)...
19 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017

SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
18 déc. 2017 08h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine

Data Published Online in Journal of Medicinal Chemistry Company Evaluating Potential Clinical Program for OPNT005 SANTA MONICA, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Opiant...
04 déc. 2017 16h05 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results

SANTA MONICA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
13 oct. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

SANTA MONICA, Calif, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
02 oct. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment

SANTA MONICA, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced a collaboration to explore...
25 sept. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis

SANTA MONICA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc., (“Opiant”) (NASDAQ:OPNT), today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to...
15 sept. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray

SANTA MONICA, Calif., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
06 sept. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

SANTA MONICA, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
05 sept. 2017 07h00 HE | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer

SANTA MONICA, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...

Page précédente